US 12,433,892 B2
Compositions and methods of treatment for neurological disorders comprising depression
Sylvain Lengacher, Geneva (CH); Charles Finsterwald, Geneva (CH); and Pierre Magistretti, Geneva (CH)
Assigned to GLIAPHARM SA, Geneva (CH)
Filed by Gliapharm SA, Geneva (CH)
Filed on Jun. 22, 2021, as Appl. No. 17/354,037.
Application 17/354,037 is a continuation in part of application No. PCT/US2019/067714, filed on Dec. 20, 2019.
Claims priority of provisional application 62/784,385, filed on Dec. 22, 2018.
Prior Publication US 2022/0040186 A1, Feb. 10, 2022
Int. Cl. A61K 31/519 (2006.01); A61K 31/135 (2006.01); A61K 31/137 (2006.01); A61K 31/138 (2006.01); A61K 31/165 (2006.01); A61K 31/18 (2006.01); A61K 31/335 (2006.01); A61K 31/343 (2006.01); A61K 31/381 (2006.01); A61K 31/402 (2006.01); A61K 31/4155 (2006.01); A61K 31/416 (2006.01); A61K 31/4188 (2006.01); A61K 31/4245 (2006.01); A61K 31/426 (2006.01); A61K 31/427 (2006.01); A61K 31/428 (2006.01); A61K 31/4365 (2006.01); A61K 31/437 (2006.01); A61K 31/4409 (2006.01); A61K 31/4439 (2006.01); A61K 31/4525 (2006.01); A61K 31/454 (2006.01); A61K 31/47 (2006.01); A61K 31/496 (2006.01); A61K 31/502 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 31/542 (2006.01); A61K 31/55 (2006.01); A61K 31/551 (2006.01); A61K 31/5513 (2006.01); A61P 25/24 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/138 (2013.01); A61K 31/165 (2013.01); A61K 31/18 (2013.01); A61K 31/335 (2013.01); A61K 31/343 (2013.01); A61K 31/381 (2013.01); A61K 31/402 (2013.01); A61K 31/4155 (2013.01); A61K 31/416 (2013.01); A61K 31/4188 (2013.01); A61K 31/4245 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/428 (2013.01); A61K 31/4365 (2013.01); A61K 31/437 (2013.01); A61K 31/4409 (2013.01); A61K 31/4439 (2013.01); A61K 31/4525 (2013.01); A61K 31/454 (2013.01); A61K 31/47 (2013.01); A61K 31/496 (2013.01); A61K 31/502 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/542 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61K 31/5513 (2013.01); A61P 25/24 (2018.01)] 10 Claims
 
1. A method of treating a neurological disease or delaying of said neurological disease, wherein said neurological disease is depression or a subtype thereof in a subject in need thereof, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula II:

OG Complex Work Unit Chemistry
wherein:
RII′ is —H;
BII is optionally substituted cyclopentyl;
XII′ is —NR*—, or optionally substituted piperidinyl, piperazinyl, or pyrrolidinyl;
XII is an optionally substituted C1-C10 alkylenyl wherein optionally one or more carbon atoms are each independently replaced by —O—, or —NR*—;
YII is optionally substituted pyridyl, optionally substituted thiophenyl, optionally substituted furanyl, optionally substituted pyrazolyl, or optionally substituted phenyl; and
each R* is independently —H or optionally substituted C1-C6 alkyl;
and a pharmaceutically acceptable carrier, diluent or excipient thereof.